Antibodies against the conserved stalk domain of the hemagglutinin are currently being discussed as promising therapeutic tools against influenza virus infections. Due to the conservation of the stalk domain these antibodies are able to broadly neutralize a wide spectrum of influenza virus strains and subtypes. Broadly protective vaccine candidates based on the epitopes of these antibodies, e.g. chimeric and headless hemagglutinin structures, are currently under development and show promising results in animals models. These candidates could be developed into universal influenza virus vaccines that protect from infection with drifted seasonal as well as novel pandemic influenza virus strains therefore obviating the need for annual vaccination, and enhancing our pandemic preparedness.
Introduction
Seasonal influenza virus infections are a major public health concern and cause significant morbidity and mortality every year worldwide. In addition, novel influenza viruses are introduced into the human population occasionally. If there is no pre-existing immunity against these strains in humans they have the potential to cause severe pandemics. Human cases of avian H7N9 in China in early spring 2013 clearly demonstrated the threat by these zoonotic viruses [1] . Influenza virus vaccines are so far the best preventive countermeasure against influenza virus infections. These vaccines induce antibodies that block the binding of the hemagglutinin (HA), the major surface glycoprotein of the influenza virus, to sialylated host cell receptors [2] . By blocking this step the virus is unable to attach to cells and the virus life cycle is interrupted early on. Antibodies with this function have very potent neutralizing activity and can readily be measured in serum using the hemagglutination inhibition (HI) assay [3] . These antibodies are directed against the membrane distal part of the HA, the globular head domain ( Figure 1A , B and D) [4] [5] [6] , which has a high plasticity and is subject to constant antigenic drift driven by human herd immunity. Therefore, antibodies that target this domain (HI-active antibodies) are very strain specific and quickly lose efficacy against drifted strains. Due to this viral mechanism to escape human herd immunity influenza virus vaccines have to be reformulated almost annually based on surveillance data from laboratories in the Northern and Southern hemispheres [7] . Vaccine strain prediction based on surveillance is a complicated and error prone process and produces mismatches between circulating virus and vaccine strains from time to time which leads to a severe drop in efficacy of the seasonal influenza virus vaccines [8] [9] [10] [11] [12] . The fact that the vaccines need to contain three to four components (an H1N1, an H3N2 and one or two influenza B virus strains) adds to the complexity of the process [7] . Furthermore, seasonal vaccines usually lack efficacy against pandemic or potential pandemic viruses which have divergent globular head domains. In the case of a new pandemic virus, vaccines have to be manufactured rapidly. However, it usually takes several months from the identification of the right vaccine seed strain to the delivery of the vaccine for use in the population. In 2009 during the H1N1 pandemic the first batches of vaccine were delivered in the US after the first pandemic wave hit -and came therefore too late [13] .
The membrane proximal stalk domain of the HA is, in contrast to the head domain, conserved among group 1, among group 2 and among influenza B viruses ( Figure 1E ). It is composed of the N-and C-terminal parts of HA1 and the N-terminal part of the HA2 subunit; the demarcation line between stalk and head domain is formed by two cysteine residues (amino acids 52 and 277, H3 numbering) that form a disulfide bond ( Figure 1A , B and D) [14, 15] . Functionally, the stalk domain mediates the fusion of viral and endosomal membranes once the virus is taken up into the cell; this function is crucial for the release of the viral genome into the cytosol [2] . During the process of fusion the stalk domain has to undergo extensive structural re-arrangements. These re-arrangements are essential for viral replication and mutations that interfere with this function are not tolerated. The plasticity of the stalk domain is therefore limited which explains its conservation and reveals a weak point of the virus that can be targeted by broadly-neutralizing antibodies, universal vaccine strategies and perhaps also by antiviral drugs.
Hemagglutinin stalk-reactive monoclonal antibodies
Antibodies against the stalk domain are generally not induced by vaccination with inactivated influenza virus vaccines and these types of antibodies are rare in humans [4, 5] . The first antibody against the stalk domain, mouse monoclonal antibody (mAb) C179, shows a broad binding and neutralization profile against multiple group 1 HA expressing viruses and was isolated in 1993 [16] (Figure 1C ). Recently, a number of mAbs against the stalk domain have been isolated from humans and mice and many of them show broad neutralizing activity against a variety of influenza virus strains and subtypes. The vast majority of stalk reactive antibodies (including CR6261, F10, FI6 and C179) share a common footprint on the stalk domain [17] [18] [19] [20] [21] . The epitope recognized by these antibodies is conformational [22] and involves HA1 as well as HA2 residues [17] [18] [19] [20] [21] . Most of these antibodies bind broadly and neutralize one (e.g. 6F12) or more (e.g. CR6261, F10, C179, KB2 or GG3) members of the group 1 HAs (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, Figure 1E ) [17] [18] [19] [20] [21] 23, 24] . Two stalk-reactive antibodies, FI6 and 05-2G02, that cover both members of group 1 and group 2 HAs (H3, H4, H7, H10, H14, H15, Figure 1E ) have been isolated as well [20, 25] . In addition, mAb CR9114 is also able to broadly bind (but not neutralize) divergent influenza B virus HAs [26] . Many of these antibodies like F10, CR6261 and CR9114 are derived from the human germline VH [17, 19, 26] . The fact that some of these antibodies make contacts only with their heavy chains might reflect the library based approach through which they were obtained [17] [18] [19] .
The broadly-neutralizing group 2 antibody CR8020 has a distinct conformational epitope on the membrane-proximal part of the stalk domain. It almost exclusively makes contact with the short alpha helix of the HA2 subunit and is so far the only described antibody that binds to this epitope [27] . Yet another neutralizing epitope is located on the long alpha helix of the HA2 and is recognized by pan-H3 mAb 12D1 [28] . Although 12D1 recognizes its epitope under denaturing conditions it is believed that the epitope is indeed microconformational [28] . In addition weakly or non-neutralizing epitopes in the stalk domain have been described [29] [30] [31] [32] [33] . So far only one stalk-reactive mAb that broadly neutralizes influenza B viruses, 5A7, has been identified [34] .
In contrast to HI active antibodies which mainly work through inhibition of viral attachment to sialylated host cell receptors stalk reactive antibodies employ various mechanisms of direct and indirect neutralization. By binding to the stalk domain of the HA of incoming virions [35] many of these antibodies inhibit pH induced conformational changes of the HA in the endosome [17, 23, 27, 28] (Figure 2 ). This mechanism prevents fusion of endosomal and viral membranes and the release of genomic material into the cytosol. HA on virus particles has to be cleaved into HA1 and HA2 subunits in order to yield infectious particles. The footprint of most stalk-reactive antibodies covers the protease cleavage site between HA1 and HA2 and antibody bound to the HA therefore prevents HA maturation [17, 20, 27] . This extracellular mechanism of action works for most influenza viruses. Strains that possess HAs with multibasic cleavage site however are cleaved intracellularly by furin-like proteases. In this case the HA is inaccessible to antibodies prior to cleavage [36] . Furthermore antibody-dependent cell-mediated cytotoxicity (ADCC) and complement mediated cytotoxicity have been shown to be involved as well [37] [38] [39] . Direct virus lysis by complement, as shown for HIV, can also not be excluded as a potential mechanism [40] .
Stalk-reactive antibodies as therapeutic measures for influenza virus infections
Neuraminidase and M2-ion channel inhibitors are excellent therapeutics for treatment of influenza virus infections. However, resistant virus variants arise quickly in immunocompromised patients and broadly-neutralizing stalk-reactive antibodies could be used as therapeutic treatment in these cases [41] [42] [43] [44] [45] [46] [47] . A number of stalk-reactive antibodies have been tested extensively in the mouse model and were able to show high efficacy even at low doses [23, 27, 48] . As an example, mouse mAb 6F12 was shown to be efficacious against H1N1 viruses spanning a period of almost one hundred years and was able to protect mice from morbidity when delivered even 5 days post infection at a 30 mg/kg dose [23] . Protective doses in mice can be as low as 1 mg/kg which is comparable to HI active antihead mAbs [23, 26, 27, 49] . It is of note that mAb CR9114, which has no in vitro neutralizing activity against influenza B viruses, is able to potently protect mice from in vivo challenge with influenza B virus [26] . As mentioned above this indicates that stalk-reactive antibodies employ alternative mechanisms of protection as well. MAbs CR6261 and 6F12 have also been evaluated in the ferret model of influenza disease and were both shown to efficiently inhibit viral replication [50, 51] . Antibodies CR6261 and CR8020 are currently being tested in human clinical trials at doses of 2 to 50 mg/kg [52, 53] . Broadly neutralizing stalk reactive antibodies might therefore become valuable additions to our therapeutic countermeasures against severe cases of influenza virus infection.
Induction of stalk-reactive antibodies by influenza viruses in nature
Stalk-reactive antibodies are not [4] [5] [6] , or very rarely [18, 54] , found in individuals vaccinated with seasonal inactivated influenza virus vaccines. Similar findings were reported in the mouse model for which vaccination of naive animals with inactivated or DNA vaccine did not induce detectible levels of stalk reactive antibodies [6, 55] . However, these antibodies are detected at low levels following natural infection with seasonal H1N1 and H3N2 influenza virus strains in humans as well as in mice [6, 55, 56] . Background levels of stalk-reactive antibodies against group 1 and group 2 HAs are found in many individuals, probably due to natural infection [6, [56] [57] [58] . In stark contrast with these findings infection of individuals with 2009 pandemic H1N1 virus induced high levels of stalk-reactive antibody responses [56, 59] . We hypothesize that induction of stalk reactive antibodies is driven in these individuals by the exposure to a hemagglutinin which has a conserved stalk but a highly divergent H1 head domain ( Figure 3 ). Individuals who were exposed to seasonal, prepandemic H1N1 virus mainly developed responses against the immunodominant globular head domain of the HA and only very low levels of B-cells with specificity for the immunosubdominant stalk domain were induced. After exposure to the 2009 pH1N1 virus, which has a divergent, roughly 30% different globular head domain, these B-cells with specificity for the conserved H1 stalk domain were boosted. This scenario could readily be reproduced in the mouse model [55] . The 2009 pandemic H1N1 strain completely replaced the pre-pandemic seasonal H1N1 strains circulating in the human population before 2009. Interestingly, the H2N2 pandemic virus from 1957 also replaced the H1N1 strains circulating prior to 1957. Both of these viruses express group 1 HAs with divergent head but conserved stalk domains. We therefore hypothesize that the increase of stalk reactive antibodies in a population who are sequentially exposed to two viruses with divergent heads but conserved stalks is a mechanism that drives elimination of the earlier strain [60] . The extinction of human H2N2 strains in 1968 after the introduction of H3N2 strains into the population might have been caused by a slightly different but related mechanism where antibodies against epitopes on the more conserved NA were boosted [60, 61] .
The described mechanism can also be applied to vaccines. Humans who received inactivated adjuvanted or non-adjuvanted pH1N1 vaccines also produced increased levels of stalkreactive antibodies [25, 48, 62] . Furthermore, we could show that vaccinees who received the H1N1 A/New Jersey/76 (NJ76) swine flu vaccine had higher levels of stalk reactive antibodies compared to individuals who did not receive this vaccine [57] . Again, the NJ76 H1N1 strain expressed an H1 HA that had a conserved stalk domain but a very divergent globular head domain as compared to seasonal H1N1 viruses circulating in humans.
In conclusion low levels of stalk reactive antibodies, mostly induced by natural infection, are present in the human population. These antibodies can be boosted under special conditions when pandemic viruses with divergent, novel globular head domains but conserved stalk domains are introduced into the population. The resulting boost of stalk-reactive antibodies constitutes a mechanism that might drive elimination of pre-pandemic seasonal viruses that express HAs from the same HA group.
Stalk-based universal influenza virus vaccine candidates
Approaches to create broadly protective vaccines based on conserved parts of the HA by removal of the immunodominant head domain were first reported in 1983 [63] (Figure 4A and E). However, these vaccine constructs were prepared using acid treatment combined with a reducing agent and neutralizing conformational epitopes were most likely denatured which explains the absence of efficacy of these preparations. Later on recombinant DNA technology made it possible to express the immunosubdominant HA2 subunit of the HA in bacteria [64] . Vaccine candidates based on these constructs partially protected mice from challenge. However, most neutralizing epitopes in the stalk domain cover the HA1 as well as the HA2 part of the stalk. A stalk-only structure that covers the HA1 and the HA2 part of the stalk domain -a 'headless' HA -was expressed successfully by Steel and colleagues by taking advantage of the naturally occurring disulfide linkage between cysteines 52 and 277 (H3 numbering, Figure 4B and F) [15] . Replacement of the globular head domain with a glycine linker resulted in a headless HA protein that partially protected mice from viral challenge. However, this construct only expressed to low levels in mammalian cells and correct folding of the construct could not be confirmed. Another approach focused solely on the epitope of 12D1, the long alpha helix [28] (Figure 4C and G). Animals vaccinated with this construct showed good homologous and partial heterologous protection demonstrating the breadth of stalk based vaccine approaches [65] . Furthermore, novel prime-boost strategies have been developed to focus the immune response on conserved regions of the HA [28, 66, 67] . However, DNA prime -protein boost strategies seem to be mostly limited to responses within one subtype [67] . Another strategy for the induction of broadly neutralizing stalk-reactive antibodies is the display of conserved stalk-epitopes on nanoparticles [68, 69] . Similar to DNA prime -protein boost strategies, nanoparticle-based immunogens seem to induce mostly subtype-specific immunity [69] .
Recently, we developed a novel approach that mimics the 2009 pH1N1 situation in nature. We constructed chimeric HA molecules (cHA) that combine H1 (group 1) or H3 (group 2) stalk domains in combination with 'exotic' head domains (e.g. H4, H5, H6, H7 or H9, Figure 4D and H) [14] . Sequential vaccination with these constructs, which always have the same stalk but divergent heads to which no cross-reactivity exists (measured by HI), boosts antibodies against conserved epitopes in the stalk domain [70] . This vaccination regimen induces high titers of stalk-reactive antibodies in mice and ferrets ( Figure 5A ) [51, 70] . It is able to protect animals from heterologous (divergent H1/H3 strains) as well as from heterosubtypic challenge (challenge with members for the same HA group). Animals vaccinated with cHAs based on the H1 stalk were protected against lethal H5N1 and H6N1 challenges and developed broadly neutralizing antibodies against other group 1 HA expressing viruses (e.g. H2N2) as well [70] . Animals vaccinated with H3 stalk based constructs showed similar broad protection that included challenge with H7N1 and H7N9 strains. It was demonstrated that the protective mechanism is mainly based on broadly neutralizing antibodies but probably includes ADCC and complement as well. In contrast to HA2 or headless HA constructs, cHAs have a globular head domain (as defined by the amino acids between C52 and C277, H3 numbering) in place which guarantees the correct folding of the stalk domain. In fact, viruses expressing these cHAs grow to high titers in embryonated eggs demonstrating the full biological activity of these constructs [14] . Chimeric HA -based vaccines could therefore be produced using various production platforms ranging from novel recombinant technologies to traditional egg-derived inactivated vaccines. A human vaccine based on inactivated influenza viruses that express cHAs and relevant NAs (recent N1 or N2) could therefore boost cross-neutralizing antibodies against the stalk domain as well as the NA which is usually also immunosubdominant in the presence of an immunodominant HA head domain. Since most adult humans already have pre-existing humoral immunity to conserved epitopes in the stalk domain it is expected that one or two immunizations would be sufficient to boost these antibody levels to neutralizing titers ( Figure 5B ). Importantly, cross-neutralization between group 1 and group 2 HAs was not observed in preclinical studies and it is therefore likely that an effective universal influenza virus vaccine has to include a group 1, a group 2 and an influenza B HA immunogen [70].
Summary and outlook
Broadly reactive antibodies directed against the stalk domain of the HA have been isolated from mice and humans. These antibodies are able to neutralize divergent influenza virus strains and subtypes and are currently being evaluated in clinical trials for their potential use as anti-influenza therapeutics. Vaccines based on conserved epitopes in the stalk domain of the HA are currently in late stage pre-clinical development. Several promising candidates, like chimeric HA immunogens, have been reported recently and show good protection of animals from challenge with divergent viral strains and subtypes. A universal influenza virus vaccine that boosts stalk-reactive antibodies in the population to high, long lasting, neutralizing titers could potentially obviate the need for an annually reformulated vaccine and would substantially enhance our pandemic preparedness. A Example for a cHA vaccination strategy in naive animals. Animals are primed with a cH9/1 construct (H9 head (black) on top of an H1 stalk (green)). The prime induces a strong primary response against the immunodominant globular head domain and an almost undetectable response against the immunosubdominant stalk domain. Animals are then boosted with a cH5/1 construct (H5 head (golden) on top of an H1 stalk domain (green)). Again, a primary response is developed against the divergent globular head but antibodies against the conserved stalk domain are boosted. A second boost with cH6/1 HA (H6 head (blue) on top of an H1 stalk domain (green)) induces a primary response against the divergent H6 head domain but strongly boosts titers of antibodies directed to the conserved stalk domain. B Similar vaccination strategies could be employed for humans. It is likely that a prime is not necessary since most individuals have been exposed to human influenza viruses and have therefore a low but detectable pre-existing immunity directed toward the stalk domain. Individuals can be boosted once (e.g. with cH5/1 HA) or twice (e.g. with cH5/1 and cH6/1 HA) to induce high, broadly neutralizing antibody titers. Structures are based on PDB 1RU7.
